Drugs / NA-931
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06615700 | May → Aug 2024 | obesity disorder, type 2 diabetes mellitus | Biomed Industries, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06564753 | Jul 2024 → Feb 2025 | obesity disorder | Biomed Industries, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06732245 Comparator | Aug 2026 → Aug 2027 expected | obesity disorder | Biomed Industries, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2025-09-30 | Biomed Industries, Inc. | Results Biomed Industries Unveils Phase 2 Success of NA-931: Oral Quadruple Receptor Agonist for Obesity at EASD 2025 biomedind.com ↗
The Phase 2 trial confirmed the robust efficacy and favorable safety profile seen in Phase 1. |
| 2025-09-08 | Biomed Industries, Inc. | Results Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at EASD 2025 Conference biomedind.com ↗
The Phase 2 trial confirmed the robust efficacy and favorable safety profile seen in Phase 1. |
| 2025-07-17 | Biomed Industries, Inc. | Results Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025 biomedind.com ↗
NA-931 represents a breakthrough approach by simultaneously targeting four metabolic hormone pathways to achieve weight loss without compromising muscle mass. |
| 2025-06-23 | Biomed Industries, Inc. | Results Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, First-in-Class Oral Quadruple Agonist, at ADA 2025 biomedind.com ↗
The 13-week MAD study showed NA-931 demonstrated dose-dependent reductions in mean body weight from baseline, up to 13.8 % at 150 mg daily dosage, or 12.4% % |
| 2025-05-05 | Biomed Industries, Inc. | Results Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025 Conference biomedind.com ↗
NA-931 achieved weight loss outcomes on par with leading approved and late-stage injectable therapies, while showing significantly fewer and milder side effects. |
| 2024-12-10 | Biomed Industries, Inc. | Results Biomed Industries presenting Combination Therapy Protocol of NA-931 and Tirzepatide at ICOCD-2025 biomedind.com ↗
This randomized, double-blind, placebo-controlled study demonstrated that NA-931 achieved a clinically meaningful weight loss with no significant gastrointestinal-related adverse events or muscle loss. |
| 2024-11-25 | Biomed Industries, Inc. | Results Biomed Industries Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder biomedind.com ↗
Preclinical studies demonstrate that NA-931 significantly attenuates alcohol-induced locomotor stimulation while reducing alcohol intake and alcohol-seeking behaviors in animal models. |
| 2024-11-04 | Biomed Industries, Inc. | Results Biomed Industries, Inc. presented Phase 1 results of NA-931, an Oral Novel Quadruple Receptor Agonist for Weight Loss at the World Obesity & Weight Management Congress 2024 biomedind.com ↗
Biomed Industries, Inc., a leading biopharmaceutical company, presented positive topline results from a Phase I clinical study of its once-daily, oral quadruple receptor agonist, NA-931, in participants with obesity, with or without type 2 diabetes. |
| 2024-10-07 | Biomed Industries, Inc. | Results Biomed Industries, Inc. Announces Positive Phase I Results of Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment biomedind.com ↗
Biomed Industries, Inc. announced positive topline results from a Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of its once-daily, oral quadruple receptor agonist, NA-931, in participants with obesity, with or without type 2 diabetes. |
| 2024-07-01 | Biomed Industries, Inc. | Results Biomed Industries, Inc. Presents NA-931 and NA-941 for Treatment of Obesity and MASH at ADA Conference and Global MASLD Congress 2024 biomedind.com ↗
NA-931™, a Novel Quadruple IGF-1/GLP-1/GIP/Glucagon Receptor Agonist Reduces Body Weight and Improves Metabolic Profile in DIO Mice |
| 2024-06-11 | Biomed Industries, Inc. | Results Biomed Industries, Inc. to Present a New Quadruple Receptor Agonist for Treatment of Obesity at ADA’s 84th Scientific Sessions and Euro Obesity Congress in June 2024 biomedind.com ↗
NA-931™, a Novel Quadruple IGF-1/GLP-1/GIP/Glucagon Receptor Agonist Reduces Body Weight and Improves Metabolic Profile in DIO Mice |
All press releases naming this drug 13 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NA-931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564753 ↗ |
| Action | Activate | “NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist” NCT06564753 ↗ |
| Modality | Peptide | “NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist” NCT06564753 ↗ |
| Route | Oral | “NA-931 dose 1, daily and orally” NCT06564753 ↗ |